Fig. 4From: Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 − metastatic or advanced breast cancer patients: a network meta-analysisForest plot of the hazard ratios for PFS based on different pairwise comparisonsBack to article page